Cannabidiol

Avicanna Reports Full Year 2023 Audited Financial Results 

Retrieved on: 
Tuesday, April 2, 2024

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce year end 2023 results and audited financial statements.

Key Points: 
  • TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce year end 2023 results and audited financial statements.
  • Cash used in operations of $1.38 million; an 81% reduction compared to $7.4 million in 2022.
  • “2023 was a tremendous year for Avicanna where we solidified of our leadership position in the Canadian medical cannabis sector through our proprietary products and the launch of MyMedi.ca.
  • We have successfully demonstrated the scalability of our revenues and made significant improvements in our fundamentals while advancing all our business pillars.

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Retrieved on: 
Monday, March 25, 2024

SOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the fiscal year ended December 31, 2023 and provided a business update.

Key Points: 
  • SOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the fiscal year ended December 31, 2023 and provided a business update.
  • “We made substantial progress on multiple programs last year,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • Cash and Investments: Cash and investments totalled $10.4 million as of December 31, 2023.
  • R&D Expenses: Research and development expenses were $5.7 million for the year ended December 31, 2023, compared to $4.3 million for the same period in 2022.

/R E M I N D E R -- Travelling for Easter? The Canada Border Services Agency gives tips for a smooth trip/

Retrieved on: 
Thursday, March 28, 2024

Here are some tips to help you plan for your trip:

Key Points: 
  • Here are some tips to help you plan for your trip:
    Plan ahead, expect delays and check border wait times .
  • Travellers crossing the border by land are encouraged to cross during non-peak hours such as early mornings.
  • Border services officers are always watching for missing children , and in the absence of the letter, officers may ask additional questions.
  • You may also contact Border Information Service (BIS) line toll-free within Canada at 1-800-461-9999 for more information

CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet Chews

Retrieved on: 
Tuesday, March 26, 2024

SAN DIEGO, March 26, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, proudly announces its latest innovation and product launch: a premier CBD chew tailored for pets, +PlusCBD™ Pet Hip and Joint Health Chews and +PlusCBD™ Pet Calming Care Chews. +PlusCBD™Pet wellness treats are crafted with the utmost care and supported by extensive research, and are now further validated by a landmark safety study backed by the National Animal Supplement Council (NASC). NASC is the leading trade association advocating for the health and wellness of companion animals that are given health supplements by their owners. The latest additions to the industry-leading +PlusCBD lineup are now available nationwide at select retailers and from our website at www.pluscbdoil.com.

Key Points: 
  • The latest additions to the industry-leading +PlusCBD lineup are now available nationwide at select retailers and from our website at www.pluscbdoil.com .
  • The pet wellness industry has witnessed a growing demand for natural alternatives to support pets' overall well-being.
  • With a THC-free formulation and non-psychoactive properties, our chews offer a safe and effective solution for pet owners seeking natural alternatives for their companions.
  • +PlusCBD™ Pet Hip and Joint Health Chews and Pet Calming Care Chews are the first new offerings from CV Sciences in 2024.

Travelling for Easter? The Canada Border Services Agency gives tips for a smooth trip

Retrieved on: 
Friday, March 22, 2024

OTTAWA, ON, March 22, 2024 /CNW/ - The Canada Border Services Agency (CBSA) reminds travellers of what to expect when crossing the border over the Easter long weekend.

Key Points: 
  • OTTAWA, ON, March 22, 2024 /CNW/ - The Canada Border Services Agency (CBSA) reminds travellers of what to expect when crossing the border over the Easter long weekend.
  • Here are some tips to help you plan for your trip:
    Plan ahead, expect delays and check border wait times .
  • Border services officers are always watching for missing children , and in the absence of the letter, officers may ask additional questions.
  • You may also contact Border Information Service (BIS) line toll-free within Canada at 1-800-461-9999 for more information

GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

Retrieved on: 
Tuesday, February 27, 2024

Professor Tal Burstyn-Cohen, Ph.D. of the Hebrew University, through the Yissum Research Development Company, led the preclinical study.

Key Points: 
  • Professor Tal Burstyn-Cohen, Ph.D. of the Hebrew University, through the Yissum Research Development Company, led the preclinical study.
  • The preclinical study aimed to assess the impact of various combinations of the neuroprotective therapeutic in a preclinical model.
  • “We are excited to finally receive the positive results from our preclinical study, which was our first step in validating our novel, cannabinoid based therapeutic,” said Aitan Zacharin, GCANRx CEO.
  • To receive the latest information about GCANRx sign up to the investor email at https://bit.ly/2ZNlBoj or follow @GCANRX on Twitter.

National Animal Supplement Council Announces Publication of Landmark Safety Study of Cannabidiol Products in Healthy Dogs

Retrieved on: 
Tuesday, March 5, 2024

The National Animal Supplement Council (NASC) today announced that Frontiers in Veterinary Science (Front.

Key Points: 
  • The National Animal Supplement Council (NASC) today announced that Frontiers in Veterinary Science (Front.
  • has published results from the first-of-its-kind peer-reviewed safety study of cannabidiol products in healthy dogs.
  • In the study, different cannabinoids were well tolerated in healthy male and female dogs when dosed for 90 consecutive days with a 14-day recovery period.
  • “These data demonstrate that different cannabidiols are safe for long-term use in healthy dogs when given at the dose studied,” said Bill Bookout, NASC President.

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

Retrieved on: 
Friday, February 23, 2024

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company has agreed to sell one of its cancer-related patent portfolios for an undisclosed amount.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company has agreed to sell one of its cancer-related patent portfolios for an undisclosed amount.
  • The patents and applications being sold disclose and claim the synergistic combination of cannabidiol and second therapeutic agents for the treatment of cancer.
  • The divested portfolio includes patents issued in the U.S., Australia, Canada, China, Europe, and Japan, with patent applications pending in Canada, Israel, and Korea.
  • Enveric retains no ownership rights in the divested portfolio, any companies owned by, or to be formed by the recipients.

Innocan Pharma's LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study

Retrieved on: 
Tuesday, March 5, 2024

HERZLIYA, Israel and CALGARY, Alberta, March 5, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug delivery technologies using CBD for the pharmaceutical and biotechnology industries, is pleased to announce the following:

Key Points: 
  • In the Company's latest study, CBD was found to be in the brains of both mice and rabbits weeks after LPT-CBD was subcutaneously injected to them.
  • These results show a strong correlation between the prolonged blood exposure of CBD and its brain distribution.
  • Sufficient exposure of CBD in the brain is the hallmark of CBD therapy associated with various neurological conditions.
  • The fact that LPT-CBD successively delivers CBD to the brain in a long-lasting manner opens a big venue for the treatment of various neurological disorders.

Charlotte's Web 2023 Fourth Quarter and Year-End Earnings Call and Webcast Notice

Retrieved on: 
Tuesday, March 5, 2024

LOUISVILLE, Colo., March 5, 2024 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") the market leader in cannabidiol (CBD) hemp extract wellness products , will report its 2023 fourth quarter and year-end results prior to market open on March 21, 2024.

Key Points: 
  • LOUISVILLE, Colo., March 5, 2024 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") the market leader in cannabidiol (CBD) hemp extract wellness products , will report its 2023 fourth quarter and year-end results prior to market open on March 21, 2024.
  • A conference call to discuss the results is scheduled for the same day at 11:00 a.m. Eastern Time.
  • To listen to a replay of the earnings call please dial 1-416-764-8677 or 1-888-390-0541 and provide conference replay ID 481810#.
  • A webcast of the call will also be accessible through the investor relations section of the Company's website for an extended period of time.